Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation
NCT00974272 on ClinicalTrials.gov · last registry update 2009-09-10
Finished November 2008, after enrolling 39 people. Primary outcome, as filed: Triglyceride concentration in serum. exenatide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Carl T. Hayden VA Medical Center
- Sponsor type
- Fed
- Enrollment
- 39
- Started
- 2006-08
- Primary completion
- 2008-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Triglyceride concentration in serum
Conditions studied
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.